Processa Pharmaceuticals (PCSA)

Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the assets of Promet Therapeutics, LLC in October of 2017 and assembled a proven regulatory science development team, management team, and Board of Directors. The Processa drug development team members have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. PCS-499 represents the first Processa drug that can potentially be used in several unmet medical need conditions.

Company profile

Ticker

PCSA

Exchange

NASDAQ

Website

processapharmaceuticals.com

CEO

David Young

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Heavy Duty Truck Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

Heatwurx, Inc.

SEC CIK

0001533743

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Processa Therapeutics LLC ...

PCSA stock data

1M 1Y 5Y

News

From Benzinga Pro

Earnings Scheduled For August 11, 2022

11 Aug 22

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

82 Biggest Movers From Yesterday

15 Jun 22

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.

41 Stocks Moving In Tuesday's Mid-Day Session

14 Jun 22

Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy.

Press releases

From Benzinga Pro

Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

12 Aug 22

PCS12852 on target to complete enrollment by SeptemberExpanded efforts to increase enrollment in PCS499 and PCS6422 showing results HANOVER, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST

5 Aug 22

HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients

Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

4 Aug 22

HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

3 Aug 22

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 Aug 22

18 Aug 22

31 Dec 22

Financial summary

Financial statements Chart PCSA financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	12.06M	12.06M	12.06M	12.06M	12.06M	12.06M
Cash burn (monthly)	776.84K	730.59K	1.72M	1.24M	776.84K	701.1K
Cash used (since last report)	1.28M	1.2M	2.84M	2.04M	1.28M	1.16M
Cash remaining	10.78M	10.86M	9.22M	10.02M	10.78M	10.91M
Runway (months of cash)	13.9	14.9	5.4	8.1	13.9	15.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

PCSA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Aug 22	Sian Bigora	Common Stock	Option exercise	Acquire M	No	No	0	7,601	0	403,019
5 Aug 22	Wendy Guy	Common Stock	Option exercise	Acquire M	No	No	0	7,601	0	189,528
5 Aug 22	Patrick Lin	Common Stock	Payment of exercise	Dispose F	No	No	3.17	2,656	8.42K	438,335
5 Aug 22	Patrick Lin	Common Stock	Option exercise	Acquire M	No	No	0	7,601	0	440,991
5 Aug 22	Geraldine Pannu	Common Stock	Option exercise	Acquire M	No	No	0	1,169	0	11,269
5 Aug 22	James H Stanker	Common Stock	Payment of exercise	Dispose F	No	No	3.17	2,462	7.8K	49,250
5 Aug 22	James H Stanker	Common Stock	Option exercise	Acquire M	No	No	0	7,601	0	51,712
5 Aug 21	Wendy Guy	Common Stock	Payment of exercise	Dispose F	No	No	3.17	1,782	5.65K	187,746

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

PCSA institutional ownership history Ownership history

84.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	21	22	-4.5%
Opened positions	2	3	-33.3%
Closed positions	3	2	+50.0%
Increased positions	3	2	+50.0%
Reduced positions	3	6	-50.0%

13F shares	Current	Prev Q	Change
Total value	52.2M	55.45M	-5.9%
Total shares	13.4M	13.65M	-1.8%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
David Young	11.44M	$45.2M	0.0%
Yuhan (usa)	750K	$2.96M	0.0%
Vanguard	373.6K	$1.13M	0.0%
AIGH Capital Management	303.7K	$915K	0.0%
Manchester Management	142.43K	$819K	0.0%
Worth Venture Partners	70.95K	$214K	0.0%
Geode Capital Management	64.9K	$195K	0.0%
Verdence Capital Advisors	59.88K	$180K	-5.3%
Janney Montgomery Scott	46.23K	$139K	0.0%
STT State Street	41.49K	$125K	0.0%

Largest transactions	Shares	Bought/sold	Change
Solas Capital Management	22.84K	-173.31K	-88.4%
Essex Investment Management	0	-73.18K	EXIT
Vectors Research Management	0	-4K	EXIT
Verdence Capital Advisors	59.88K	-3.34K	-5.3%
WFC Wells Fargo & Co.	3.14K	+3.08K	+4882.5%
Tower Research Capital	3.13K	+1.52K	+94.3%
BLK Blackrock	29.09K	-1.41K	-4.6%
UBS UBS Group AG - Registered Shares	1.12K	+897	+411.5%
Whittier Trust	22	+22	NEW
BAC Bank Of America	0	-7	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Continental, director, ensure, Equiniti, floor, hinder, modification, originally, put, rare, ratably, recommended, reelection, run, Trust, unamortized, unexpected, unknown

Removed: activate, assay, attributable, biomarker, continuing, depreciation, determining, existing, measurement, medicine, precision, refining, specifically

From filing 10-Q 2022 Q2

Financial reports

View all